AB
STRO icon

Amalgamated Bank’s Sutro Biopharma STRO Stock Holding History

Amalgamated Bank’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-283
Closed -$2K – 3138
2025
Q1 		$2K Buy
283
+87
+44% +$1.37K ﹤0.01% 2872
2024
Q4 		$4K Hold
196
– – ﹤0.01% 2812
2024
Q3 		$7K Hold
196
– – ﹤0.01% 2642
2024
Q2 		$6K Hold
196
– – ﹤0.01% 2725
2024
Q1 		$11K Sell
196
-315
-62% -$13.9K ﹤0.01% 2408
2023
Q4 		$22K Sell
511
-59
-10% -$1.87K ﹤0.01% 2611
2023
Q3 		$20K Hold
570
– – ﹤0.01% 2666
2023
Q2 		$26K Hold
570
– – ﹤0.01% 2614
2023
Q1 		$26K Sell
570
-82
-13% -$5.2K ﹤0.01% 2554
2022
Q4 		$53K Buy
652
+51
+8% +$3.54K ﹤0.01% 2393
2022
Q3 		$33K Buy
601
+46
+8% +$2.72K ﹤0.01% 2641
2022
Q2 		$29K Buy
555
+17
+3% +$950 ﹤0.01% 2741
2022
Q1 		$44K Buy
+538
New +$51.2K ﹤0.01% 2538

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Amalgamated Bank's STRO Position: Q2 2025 in Review

Amalgamated Bank sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 283 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in STRO in Q1 2022 and held it in 13 quarters. The position peaked at $53K in Q4 2022. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • Amalgamated Bank reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 283 Sutro Biopharma shares in Q2 2025, an estimated $2K.
  • Amalgamated Bank first reported a position in Sutro Biopharma in Q1 2022 and held it in 13 quarters.
  • Amalgamated Bank's Sutro Biopharma position peaked at $53K in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.